ArticleMolecular imaging and biology2013
MRI of ICAM-1 upregulation after stroke: the importance of choosing the appropriate target-specific particulate contrast agent.
Article in Molecular imaging and biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Neutrophil-Mimetic MRI Enables Ultra-Early Detection of Vascular Inflammation After Stroke.Advanced healthcare materials · 2026Article
- In vivo methods for imaging blood-brain barrier function and dysfunction.European journal of nuclear medicine and molecular imaging · 2023Review
- Nanoparticles in the diagnosis and treatment of vascular aging and related diseases.Signal transduction and targeted therapy · 2022Review
- New Approaches in Nanomedicine for Ischemic Stroke.Pharmaceutics · 2021Review
- Current Approaches and Future Perspectives for Nanobodies in Stroke Diagnostic and Therapy.Antibodies (Basel, Switzerland) · 2019Review
- A Systems Analysis of the Relationships Between Anemia and Ischemic Stroke Rehabilitation Based on RNA-Seq Data.Frontiers in genetics · 2019Article
- Cellular magnetic resonance imaging: in vivo tracking of gastric cancer cells and detecting of lymph node metastases using microparticles of iron oxide in mice.Cancer management and research · 2019Article
- Molecular Magnetic Resonance Imaging of Endothelial Activation in the Central Nervous System.Theranostics · 2018Review
- Uric Acid Is Protective After Cerebral Ischemia/Reperfusion in Hyperglycemic Mice.Translational stroke research · 2017Article
- In Vivo Molecular MRI of ICAM-1 Expression on Endothelium and Leukocytes from Subacute to Chronic Stages After Experimental Stroke.Translational stroke research · 2017Article
- Label-free CEST MRI Detection of Citicoline-Liposome Drug Delivery in Ischemic Stroke.Theranostics · 2016Article
- Iron Oxide as an MRI Contrast Agent for Cell Tracking.Magnetic resonance insights · 2015Review
- Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents.Nanomedicine (London, England) · 2015Review
- Magnetic Resonance Imaging of Atherosclerosis Using CD81-Targeted Microparticles of Iron Oxide in Mice.BioMed research international · 2015Article
- Imaging Neuroinflammation - from Bench to Bedside.Journal of clinical & cellular immunology · 2014Article
- Molecular magnetic resonance imaging of brain-immune interactions.Frontiers in cellular neuroscience · 2014Review
- Getting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrier.International journal of nanomedicineReview
- MRI/MRS in neuroinflammation: methodology and applications.Clinical and translational imagingReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMagnetic resonance imaging (MRI) with targeted contrast agents provides a promising means for diagnosis and treatment monitoring after cerebrovascular injury. Our goal was to demonstrate the feasibility of this approach to detect the neuroinflammatory biomarker intercellular adhesion molecule-1 (ICAM-1) after stroke and to establish a most efficient imaging procedure. PROCEDURES: We compared two types of ICAM-1-functionalized contrast agent: T 1-shortening gadolinium chelate-containing liposomes and T2(*)-shortening micron-sized iron oxide particles (MPIO). Binding efficacy and MRI contrast effects were tested in cell cultures and a mouse stroke model.
resultsBoth ICAM-1-targeted agents bound effectively to activated cerebrovascular cells in vitro, generating significant MRI contrast-enhancing effects. Direct in vivo MRI-based detection after stroke was only achieved with ICAM-1-targeted MPIO, although both contrast agents showed similar target-specific vascular accumulation.
conclusionsOur study demonstrates the potential of in vivo MRI of post-stroke ICAM-1 upregulation and signifies target-specific MPIO as most suitable contrast agent for molecular MRI of cerebrovascular inflammation.
Indexed as
Identifiers
23400400What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.